Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
暂无分享,去创建一个
S. Steinberg | T. Greten | O. Rahma | D. Liewehr | A. Duffy | Tim F. Greten | Tim F Greten
[1] D. Hedley,et al. Phase II trial of erlotinib in advanced pancreatic cancer (PC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Tas,et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer , 2013, International Journal of Clinical Oncology.
[3] V. Heinemann,et al. Systemic treatment of advanced pancreatic cancer. , 2012, Cancer treatment reviews.
[4] Derek S. Chan,et al. The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.
[5] V. Velculescu,et al. Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing , 2012, Clinical Cancer Research.
[6] Y. Ko,et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) , 2012, Gut.
[7] A. Hinke,et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.
[8] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[9] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[10] M. Reni,et al. Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial , 2011, Chemotherapy.
[11] M. Tempero,et al. A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Weiner,et al. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma , 2011, American journal of clinical oncology.
[13] D. Mavroudis,et al. Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial , 2011, Cancer Chemotherapy and Pharmacology.
[14] B. Chauffert,et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) , 2010, Gut.
[15] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[16] P. Bejarano,et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. , 2010 .
[17] D. Park,et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer , 2009, British Journal of Cancer.
[18] C. Grávalos,et al. Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Xiaobai Li,et al. Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study , 2009, Oncology.
[20] J. Schlesselman,et al. Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer , 2009, Oncology.
[21] M. Pino,et al. Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers , 2009, Oncology.
[22] B. Dörken,et al. Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study , 2009, Oncology Research and Treatment.
[23] A. Novarino,et al. Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer , 2009, American journal of clinical oncology.
[24] Jeffrey W. Clark,et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Godefridus J Peters,et al. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.
[26] K. Hess,et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.
[27] J. Neoptolemos,et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.
[28] M. Tempero,et al. A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) , 2008 .
[29] B. Dörken,et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study , 2008 .
[30] R. Goldberg,et al. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603 , 2008 .
[31] M. Reni,et al. PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy , 2008, American journal of clinical oncology.
[32] G. Gallick,et al. Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.
[33] Alona Muzikansky,et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Labianca,et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. Miyazaki,et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study , 2007, International Journal of Clinical Oncology.
[36] V. Georgoulias,et al. A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer , 2007, Oncology.
[37] J. K. Lee,et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer , 2007, Cancer Chemotherapy and Pharmacology.
[38] E. Roman,et al. Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer , 2007 .
[39] G. Colucci,et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] F. Lordick,et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] T. Boulikas,et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. , 2006, Oncology reports.
[43] M. Ducreux,et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. , 2006, Gastroenterologie clinique et biologique.
[44] A. Brandes,et al. Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer , 2006, British Journal of Cancer.
[45] F. Gay,et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study , 2006, British Journal of Cancer.
[46] Y. Hao,et al. DEPLETION OF HEAT SHOCK PROTEIN-70 (HSP70) CAUSES APOPTOSIS IN PANCREATIC CANCER CELLS , 2005 .
[47] E. Felekouras,et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study , 2005, Investigational New Drugs.
[48] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] H. Burris,et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. , 2005, The oncologist.
[50] K. Syrigos,et al. Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study , 2005, Cancer investigation.
[51] A. Manni,et al. Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer , 2004, Oncology.
[52] H. Burris,et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Cosimo,et al. Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma , 2004, Cancer.
[54] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] W. Scheithauer,et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma , 2003, British Journal of Cancer.
[56] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Goldberg. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer. , 2002, Clinical colorectal cancer.
[58] D. Girling. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.
[59] P. Homel,et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. , 2001, The oncologist.
[60] D. Huhn,et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma , 2000, Anti-cancer drugs.
[61] D. Winchester,et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. , 1999, Journal of the American College of Surgeons.
[62] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[63] S Marsoni,et al. The phase II trial. , 1985, Cancer treatment reports.
[64] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[65] H. Ueno,et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer , 2008, Cancer Chemotherapy and Pharmacology.
[66] H. Burris,et al. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. , 1997, European journal of cancer.